Skip to content
Inciteful Med

The Biology of CMT1A: Symptoms and Causes

Last updated:

Charcot-Marie-Tooth disease type 1A (CMT1A) is an inherited neurological disorder caused by an extra copy of the PMP22 gene. This genetic duplication damages the myelin surrounding peripheral nerves, leading to early symptoms like high foot arches, frequent tripping, hand and foot weakness, and fatigue.

Key Takeaways

  • • CMT1A is caused by an extra copy of the PMP22 gene, which overproduces a protein that is toxic to the protective myelin around your nerves.
  • • The breakdown of myelin slows down nerve signals and can eventually damage the underlying nerve fibers, leading to permanent muscle weakness.
  • • Early physical symptoms often include very high foot arches, hammer toes, frequent tripping, and weakness in the hands and feet.
  • • Disease severity can vary widely even within the same family due to secondary genetic factors and lifestyle conditions like diabetes.
  • • Preimplantation genetic testing (PGT-M) with IVF offers a pathway for prospective parents to have children without passing on the CMT1A duplication.

Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form of CMT, a group of inherited disorders that affect the peripheral nerves [1][2]. These nerves carry signals between the brain and the rest of the body, controlling muscle movement and relaying sensory information like touch and pain. Understanding the biological “blueprint” of CMT1A can help you better manage the condition and prepare for conversations with your care team.

The Biological Cause: The PMP22 Duplication

The primary cause of CMT1A is a genetic “extra copy” of the PMP22 gene [3]. Normally, a person has two copies of this gene (one from each parent). In CMT1A, a segment of DNA is duplicated, resulting in three copies [3][4].

This extra genetic material leads to an overproduction of the PMP22 protein [3]. This protein is a critical building block for Schwann cells, which are specialized cells that create myelin—the protective, fatty insulation around your nerves [5][6]. Having too much PMP22 protein is toxic to these cells, disrupting their ability to maintain healthy myelin [4][6].

How Nerves are Affected: Demyelination

Because the Schwann cells cannot function properly, the myelin sheath begins to break down, a process called demyelination [3][7].

  • Slower Signals: Without healthy insulation, electrical signals travel much more slowly along the nerves [8][9].
  • Nerve Hypertrophy: As the body attempts to “repair” the damaged myelin, the nerves can become physically enlarged or thickened, a feature known as nerve hypertrophy [10].
  • Secondary Axon Loss: While the primary problem is the “insulation” (myelin), the “wire” inside (the axon) can also eventually become damaged or lost over time, leading to permanent muscle weakness [11].

Common Symptoms and Early Signs

CMT1A symptoms typically emerge in childhood or adolescence, though they can sometimes appear later in life [1].

  • Foot Deformities: Many patients develop pes cavus (very high arches) and “hammer toes” [12]. These changes occur because the small muscles in the feet weaken, allowing stronger muscles to pull the foot out of alignment [13].
  • Gait and Balance: Early signs in children often include persistent toe-walking or frequent tripping [14]. Adults may experience a “foot drop,” where it is difficult to lift the front of the foot while walking.
  • Distal Weakness: Weakness usually starts in the “distal” parts of the body—the hands and feet [1]. This can make tasks like buttoning a shirt or handwriting significantly more difficult [15].
  • Sensory Changes & Pain: While CMT1A is primarily a motor disease, it also affects sensory fibers, leading to numbness, tingling, or chronic pain [16][17].
  • Fatigue: Many patients report high levels of physical and mental fatigue, which can be as impactful as the physical weakness [17].

Understanding “Phenotypic Variability”

One of the most confusing aspects of CMT1A is phenotypic variability—the fact that the disease can look very different even between family members who have the exact same genetic duplication [18][19]. One person might have mild symptoms and remain highly active, while their sibling might require walking aids [18].

Scientists believe this variability is caused by:

  1. Genetic Modifiers: Other “background” genes that might protect or worsen the effects of the PMP22 duplication [19][20].
  2. Lifestyle & Health Factors: Conditions like diabetes or a high BMI can significantly worsen CMT1A symptoms and speed up nerve damage [11][21].

Inherited vs. “De Novo” Cases and Family Planning

While CMT1A is usually inherited from a parent in an autosomal dominant pattern (meaning a parent with the duplication has a 50% chance of passing it to each child), it can also occur de novo [22]. A de novo case means the duplication happened spontaneously during the formation of the egg or sperm, and the parents do not have the condition themselves [22]. Interestingly, some studies suggest that de novo cases may occasionally result in a milder version of the disease than inherited cases [22][9].

Because of the 50% inheritance risk in typical cases, family planning can be a significant source of anxiety. It is highly recommended to seek genetic counseling to understand your options. Modern family planning strategies, such as In Vitro Fertilization (IVF) with Preimplantation Genetic Testing (PGT-M), allow prospective parents to test embryos for the PMP22 duplication before implantation, providing a pathway to have children without passing on the condition.

Frequently Asked Questions

What causes Charcot-Marie-Tooth disease type 1A (CMT1A)?
CMT1A is primarily caused by an extra copy, or duplication, of the PMP22 gene. This extra genetic material causes your body to overproduce a specific protein that is toxic to the cells protecting your nerves, eventually leading to nerve damage and muscle weakness.
What are the early signs and symptoms of CMT1A?
Early signs often appear in childhood or adolescence and include foot deformities like very high arches (pes cavus) or hammer toes. Children may persistently walk on their toes or trip frequently, while adults might develop a 'foot drop' making it hard to lift the front of the foot.
Why do symptoms of CMT1A vary so much between family members?
The severity of CMT1A symptoms can differ greatly even among family members with the exact same genetic mutation. This variability is driven by other 'background' genes as well as lifestyle factors, such as diabetes or high body mass index, which can worsen nerve damage.
Can CMT1A happen if no one else in my family has it?
Yes, CMT1A can occur spontaneously in what is known as a 'de novo' case. This means the gene duplication happened randomly during conception, even though neither parent has the condition or the genetic mutation themselves.
How can I prevent passing CMT1A to my children?
Through genetic counseling, prospective parents can explore family planning strategies like In Vitro Fertilization (IVF) combined with Preimplantation Genetic Testing (PGT-M). This allows doctors to test embryos for the PMP22 duplication before implantation, ensuring the condition is not passed on.

Questions for Your Doctor

  • • How does the PMP22 duplication specifically affect the Schwann cells in my or my child's nerves?
  • • Are there signs of hidden hearing loss or speech-in-noise difficulties that we should be monitoring?
  • • Should we be screened for metabolic factors, like high BMI or glucose intolerance, that could worsen CMT1A symptoms?
  • • Given the phenotypic variability, what are the most reliable early indicators that my child's symptoms may be changing?
  • • If this is a 'de novo' case, what is the risk of passing this on to future children, and should we consider genetic counseling?

Questions for You

  • • When did you first notice changes in walking, balance, or foot shape (like high arches)?
  • • Do you or your child experience 'hidden' symptoms like significant fatigue or difficulty hearing in noisy rooms?
  • • How do symptoms like hand weakness or slow handwriting affect daily activities or schoolwork?
  • • Have you noticed a pattern of toe-walking or frequent tripping in your child?
  • • Are there other family members with similar symptoms, even if they were never formally diagnosed?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    High glucose level as a modifier factor in CMT1A patients.

    Secchin JB, Leal RCC, Lourenço CM, et al.

    Journal of the peripheral nervous system : JPNS 2020; (25(2)):132-137 doi:10.1111/jns.12379.

    PMID: 32347995
  2. 2

    Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).

    Prukop T, Stenzel J, Wernick S, et al.

    PloS one 2019; (14(1)):e0209752 doi:10.1371/journal.pone.0209752.

    PMID: 30650121
  3. 3

    Antisense oligonucleotides offer hope to patients with Charcot-Marie-Tooth disease type 1A.

    Shy ME

    The Journal of clinical investigation 2018; (128(1)):110-112.

    PMID: 29199996
  4. 4

    PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models.

    Zhao HT, Damle S, Ikeda-Lee K, et al.

    The Journal of clinical investigation 2018; (128(1)):359-368.

    PMID: 29202483
  5. 5

    PMP22 duplication dysregulates lipid homeostasis and plasma membrane organization in developing human Schwann cells.

    Prior R, Silva A, Vangansewinkel T, et al.

    Brain : a journal of neurology 2024; (147(9)):3113-3130 doi:10.1093/brain/awae158.

    PMID: 38743588
  6. 6

    The "CMT Rat": Peripheral Neuropathy and Dysmyelination Caused by Transgenic Overexpression of PMP22.

    Niemann S, Sereda MW, Rossner M, et al.

    Annals of the New York Academy of Sciences 1999; (883(1)):254-261 doi:10.1111/j.1749-6632.1999.tb08587.x.

    PMID: 29086932
  7. 7

    Aberrant Molecular Myelin Architecture in Charcot-Marie-Tooth Disease Type 1A and Hereditary Neuropathy With Liability to Pressure Palsies.

    Moss KR, Arowolo MA, Gutierrez DR, Höke A

    Glia 2026; (74(2)):e70124 doi:10.1002/glia.70124.

    PMID: 41400104
  8. 8

    Young infants with PMP22 duplication can have minor nerve conduction study abnormalities.

    Davion JB, Cassim F, Péréon Y, Nguyen The Tich S

    Neurophysiologie clinique = Clinical neurophysiology 2022; (52(6)):482-485 doi:10.1016/j.neucli.2022.09.007.

    PMID: 36253232
  9. 9

    Intermediate conduction velocity in two cases of Charcot-Marie-Tooth disease type 1A.

    Tomaselli PJ, Blake J, Polke JM, et al.

    European journal of neurology 2024; (31(5)):e16199 doi:10.1111/ene.16199.

    PMID: 38409938
  10. 10

    Evidence of nerve hypertrophy in patients with inclusion body myositis on lower limb MRI.

    Elmansy M, Morrow JM, Shah S, et al.

    Muscle & nerve 2022; (66(6)):744-749 doi:10.1002/mus.27728.

    PMID: 36151728
  11. 11

    Coexistence of Charcot Marie Tooth disease type 1A and diabetes in Taiwan: A clinicopathological study.

    Chao HC, Chou CT, Lee YC, Lin KP

    Journal of the neurological sciences 2015; (358(1-2)):213-20.

    PMID: 26349404
  12. 12

    The current status of Charcot-Marie-Tooth disease type 1 A treatment.

    Qi H, Wang X, Wu B, et al.

    Acta neurologica Belgica 2025; (125(6)):1525-1533 doi:10.1007/s13760-025-02881-1.

    PMID: 40864398
  13. 13

    Plantar Pressure Distribution in Charcot-Marie-Tooth Disease: A Systematic Review.

    Arceri A, Mazzotti A, Sgubbi F, et al.

    Sensors (Basel, Switzerland) 2025; (25(14)) doi:10.3390/s25144312.

    PMID: 40732443
  14. 14

    A comparative phenotypic analysis of a heterogeneous PMP22 cohort presenting with persistent toe-walking versus classic PMP22-related Neuropathies.

    Pomarino D, Rostásy KM, Fregien B, et al.

    Global medical genetics 2026; (13(1)):100081 doi:10.1016/j.gmg.2025.100081.

    PMID: 41551139
  15. 15

    Handwriting difficulties of children with Charcot-Marie-Tooth disease type 1A.

    Kunovsky D, Cordier R, Bray P, Burns J

    Journal of the peripheral nervous system : JPNS 2017; (22(1)):34-38 doi:10.1111/jns.12198.

    PMID: 27917570
  16. 16

    Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder.

    Duchesne M, Danigo A, Richard L, et al.

    Journal of neuropathology and experimental neurology 2018; (77(4)):274-281 doi:10.1093/jnen/nly001.

    PMID: 29408953
  17. 17

    Patient-Reported Symptom Burden of Charcot-Marie-Tooth Disease Type 1A: Findings From an Observational Digital Lifestyle Study.

    Thomas FP, Saporta MA, Attarian S, et al.

    Journal of clinical neuromuscular disease 2022; (24(1)):7-17 doi:10.1097/CND.0000000000000426.

    PMID: 36005469
  18. 18

    Association of miR-149 polymorphism with onset age and severity in Charcot-Marie-Tooth disease type 1A.

    Nam SH, Kanwal S, Nam DE, et al.

    Neuromuscular disorders : NMD 2018; (28(6)):502-507 doi:10.1016/j.nmd.2018.04.002.

    PMID: 29729827
  19. 19

    Modifier Gene Candidates in Charcot-Marie-Tooth Disease Type 1A: A Case-Only Genome-Wide Association Study.

    Tao F, Beecham GW, Rebelo AP, et al.

    Journal of neuromuscular diseases 2019; (6(2)):201-211 doi:10.3233/JND-190377.

    PMID: 30958311
  20. 20

    Testing SIPA1L2 as a modifier of CMT1A using mouse models.

    Murray GC, Hines TJ, Tadenev ALD, et al.

    Journal of neuropathology and experimental neurology 2024; (83(5)):318-330 doi:10.1093/jnen/nlae020.

    PMID: 38472136
  21. 21

    Effectiveness of Sitagliptin and Empagliflozin Combination Therapy in a Patient With Charcot-Marie-Tooth Disease and Comorbid Diabetes Mellitus: A Case Report.

    Wada M, Mizuno Y, Kajiyama A, et al.

    Cureus 2025; (17(8)):e89954 doi:10.7759/cureus.89954.

    PMID: 40951209
  22. 22

    Paternal gender specificity and mild phenotypes in Charcot-Marie-Tooth type 1A patients with de novo 17p12 rearrangements.

    Lee AJ, Nam DE, Choi YJ, et al.

    Molecular genetics & genomic medicine 2020; (8(9)):e1380 doi:10.1002/mgg3.1380.

    PMID: 32648354

This page provides educational information about CMT1A biology and symptoms. It does not replace professional medical advice. Always consult a neurologist or genetic counselor regarding your diagnosis and family planning options.

Stay up to date

Get notified when new research about Charcot-Marie-Tooth disease type 1A is published.

No spam. Unsubscribe anytime.